| Autor: |
John S. Barbieri, MD, MBA, Vatinee Y. Bunya, MD, MSCE, Mina Massaro-Giordano, MD, David J. Margolis, MD, PhD |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
JAAD International, Vol 4, Iss , Pp 1-9 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3287 |
| DOI: |
10.1016/j.jdin.2021.03.009 |
| Popis: |
Background: Although dupilumab has been associated with the development of conjunctivitis, little is known about other ocular surface disorders such as dry eye and how these side effects are managed. Objective: To evaluate the incidence and management of ocular surface disorders, including dry eye and conjunctivitis, among patients treated with dupilumab. Methods: Using US claims data, we evaluated the incidence of encounters for ocular surface disorders among patients treated with dupilumab. Secondary outcomes included ophthalmic medication use. A propensity score matched, active-comparator, new-user cohort design was used to compare the incidence of ocular surface disorders between those starting dupilumab versus methotrexate. Results: Among those with a history of atopic dermatitis, encounters for ocular surface disorders were more common in the 6 months after starting dupilumab than in the 6 months prior (11.7% versus 8.7%, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
